Pernix Therapeutics Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Pernix Therapeutics (PTX) PT Trimmed to $14 at Brean Capital Amid Weak Q2
August 7, 2015 8:57 AM EDTBrean Capital analyst Difei Yang lowered the price target on Pernix Therapeutics (NASDAQ: PTX) to $14.00 (from $17.00) following weak Q2, but maintianed a Buy rating.
Yang commented, "Q2 was a weak quarter for revenue and EPS. Management lowered guidance for a second... More
Pernix Therapeutics (PTX) Misses Q2 EPS by 15c
August 6, 2015 8:42 AM EDTPernix Therapeutics (NASDAQ: PTX) reported Q2 EPS of ($0.10), $0.15 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $47 million versus the consensus estimate of $50.7 million.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
... More